Abstract: Condensed nitrogen heterocycles, process for their preparation, and their use as antimycoticsThe invention relates to compounds of the formula ##STR1## in which two of the symbols A, B, D and E in each case are CR.sup.1 and the remaining two symbols are in each case CH or in each case nitrogen or one of the remaining two symbols is CH and the other is nitrogen and one of the symbols V and W is CR.sup.2 and the other is CH or nitrogen, R.sup.1 and R.sup.2 are in each case H, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy, X is optionally substituted imino, S, SO or SO.sub.2, Y is a bond or alkanediyl, Q is substituted cycloalkyl or substituted 4-piperidinyl, to processes for the preparation, to compositions containing them, and to their use as pesticides, fungicides and antimycotic agents.
Type:
Grant
Filed:
January 11, 1996
Date of Patent:
October 13, 1998
Assignee:
Hoechst Schering AgrEvo GmbH
Inventors:
Wolfgang Schaper, Martin Markl, Rainer Preuss, Robert Klein, Gerhard Salbeck, deceased, Peter Braun, Werner Knauf, Burkhard Sachse, Anna Waltersdorfer, Manfred Kern, Peter Lummen, Werner Bonin
Abstract: The invention concerns aniline derivatives of formula I ##STR1## wherein m is 1, 2 or 3, n is 0, 1, 2 or 3, Q is phenyl or naphthyl or a 5- or 6-membered heteroaryl moiety containing 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulfur, and X, R.sup.1 and R.sup.2 are defined in the claims; or pharmaceutical compositions containing them, and the methods of using the compounds as tyrosine kinase inhibitors and for the treatment of proliferative diseases such as cancer.
Type:
Grant
Filed:
May 21, 1997
Date of Patent:
October 13, 1998
Assignee:
Zeneca Limited
Inventors:
Dearg Sutherland Brown, Jeffrey James Morris, Andrew Peter Thomas
Abstract: This invention relates to pyridone-carboxylic acid derivatives of the following formula or salts thereof: ##STR1## wherein R.sub.1 is a hydrogen atom, a halogen atom, etc.,R.sub.2 is a carboxyl group etc.,R.sub.3 is a hydrogen atom etc.,A is a nitrogen atom or CH,m is 1 or 2, andY is an eliminable group or a group having the following formula: ##STR2## wherein R.sub.4 is a hydrogen atom or a lower alkyl group,Z is a hydrogen atom, a lower alkyl group, etc.,R.sub.5 is a hydrogen atom, a lower alkyl group, etc.,n is 0 or 1, andp is 1, 2, 3 or 4and to processes for the preparation of these compounds, and further to anti-tumor agents which contain the above compounds as effective ingredients.
Abstract: The invention concerns quinazoline compounds of the formula I ##STR1## wherein Q.sup.1 is a 5- or 6-membered heteroaryl moiety and Q.sup.1 optionally bears up to 3 substituents;wherein m is 1 or 2 and each R.sup.1 may be a group such as hydrogen, halogeno and trifluoromethyl;and wherein Q.sup.2 is phenyl which optionally bears up to 3 substituents; or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative disease such as cancer.
Abstract: A chymase inhibitor containing as its effective ingredient a quinazoline derivative, or a pharmaceutically acceptable salt thereof, having the formula (1): ##STR1## and a pharmaceutical preparation for the prevention of cardiac and circulatory system diseases derived from abnormal exacerbation of Ang II production containing the same as its effective ingredient.
Abstract: Certain benzoxazinones are useful in the inhibition of HIV reverse transcriptase (including its resistant varieties), the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Type:
Grant
Filed:
March 12, 1997
Date of Patent:
September 22, 1998
Assignee:
Merck & Co., Inc.
Inventors:
Steven D. Young, Linda S. Payne, Susan F. Britcher, Lekhanh O. Tran, William C. Lumma, Jr.
Abstract: The present invention relates to COX-2 inhibitors of the formula: ##STR1## wherein, A=halogen, C.sub.1 -C.sub.6 alkyl, SR.sup.1 or OR.sup.1 ;B=O, or H,H;X=Br or Cl;L=5-,6- or 7-membered heteroatom containing rings and is preferrably a 5-membered heteroaromatics such as thiazole, oxazole, imidazole, or oxadiazole;n=1-6, wherein the (C) is optionally branched;R=optionally substituted aryl wherein aryl is selected from phenyl, pyridyl, naphthyl, benzothienyl, or quinoxolyl, alkyl, carboxyl, esters, amino, amide, or urea; andR.sup.1 =alkyl. The compounds are useful as research tools and could be useful as potential therapeutic agents in the inhibition of the PGHS-2 isozyme and in the treatment of inflammation in mammals including humans or other conditions associated with the production of prostaglandins.
Type:
Grant
Filed:
March 4, 1997
Date of Patent:
September 22, 1998
Assignee:
Abbott Laboratories
Inventors:
Keith W. Woods, Richard W. McCroskey, Michael R. Michaelides
Abstract: The invention relates to novel 1,6-naphthyridonecarboxylic acid derivatives, to processes for their preparation, to antibacterial compositions and feed additives in which they are present, and to novel intermediates for the preparation of these active compounds.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
September 22, 1998
Assignee:
Bayer Aktiengesellschaft
Inventors:
Stephan Bartel, Klaus Grohe, Hermann Hagemann, Klaus-Dieter Bremm, Rainer Endermann
Abstract: A primer activator composition useful in cleaning and activating metallic surfaces in preparation for use with an anaerobic adhesive. The composition contains a non-combustible, non-ozone depleting, liquid polyfluoroalkane having at least one carbon-hydrogen bond, preferably a C.sub.4-10 dihydro- or trihydro-polyfluoroalkane; an alkanol which is capable of forming an azeotropic mixture with the polyfluoroalkane, preferably a C.sub.1-6 alkanol, such as n-butanol; a transition metal compound, preferably a copper compound; and optionally, an amine co-activator.
Abstract: Novel compounds of Formula (7.0a), (7.0b) or (7.0c): ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula (7.0a), (7.0b) or (7.0c) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.
Abstract: Compounds of general formula I and their salts and solvates are antifungal agents and as such are useful in the treatment of various fungal infections. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.
Type:
Grant
Filed:
March 31, 1997
Date of Patent:
September 15, 1998
Assignee:
J. Uriah & Cia. S.A.
Inventors:
Javier Bartroli, Enric Turmo, Manuel Anguita
Abstract: A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sup.25)(R.sup.48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
September 15, 1998
Assignee:
Schering Corporation
Inventors:
W. Robert Bishop, Ronald J. Doll, Alan K. Mallams, F. George Njoroge, Joanne M. Petrin, John J. Piwinski, Ronald L. Wolin, Arthur G. Taveras, Stacy W. Remiszewski
Abstract: Novel compounds of Formula ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the above formula to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.
Type:
Grant
Filed:
September 13, 1996
Date of Patent:
September 1, 1998
Assignees:
Schering Corporation, Pharmacopeia, Inc.
Inventors:
Adriano Afonso, John J. Baldwin, Ronald J. Doll, Ge Li, Alan K. Mallams, F. George Njoroge, Dinanath F. Rane, John C. Reader, Randall R. Rossman
Abstract: The present invention provides processes for making compounds of the structure(Q--L.sup.1)--L--(L.sup.2 --B)wherein(I) Q is a quinolone moiety;(II) B is a lactam moiety; and(III) L, L.sup.1, and L.sup.2 together comprise a linking moiety;comprising the steps of:(1) coupling a compound of Formula (III) with a lactam-containing compound to form an intermediate compound; and(2) cyclizing the intermediate by reaction with an organosilicon compound to give a compound of the formula (Q--L.sup.1)--L--(L.sup.2 --B).Preferably, the process additionally comprises a step prior to the coupling step, wherein protected forms of the compound of Formula (III) and the lactam compound are formed; and deprotection steps after the cyclization step, wherein the protecting groups are removed. Preferred antimicrobial compounds made by these processes are those where the beta-lactam moiety is a penem, a carbapenem, a cephem, or a carbacephem. Also preferred are those compounds where L.sup.1, L, and L.sup.
Type:
Grant
Filed:
November 12, 1997
Date of Patent:
September 1, 1998
Assignee:
The Procter & Gamble Company
Inventors:
Jared Lynn Randall, Jane Ellen Godlewski
Abstract: An improvement is described in all purpose cleaning or microemulsion compositions more environmentally friendly, which is especially effective in the removal of oily and greasy soil and having an evidenced grease release effect, contains an anionic detergent, an alkoxylated polyhydric alcohol, a hydrocarbon ingredient, and water.
Type:
Grant
Filed:
July 9, 1996
Date of Patent:
August 25, 1998
Assignee:
Colgate-Palmolive Co
Inventors:
Anne-Marie Misselyn, Patrick Durbut, Guy Broze
Abstract: New qunazolinyl-amino derivatives useful as .alpha..sub.1 -adrenoreceptor blockers are described. These compounds can be used as therapeutic agents for treating afflictions and diseases related to hyperactivity of the .alpha.-adrenergic system, such as, for example, arterial hypertension, prostate benign hyperplasia, high intraocular pressure and hpercholesterolemia. Processes for the preparation of the above said compounds are also described.
Type:
Grant
Filed:
September 17, 1996
Date of Patent:
August 25, 1998
Assignee:
Recordati S.A. Chemical and Pharmaceutical Company
Inventors:
Amedeo Leonardi, Gianni Motta, Carlo Boi, Rodolfo Testa
Abstract: Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N(C.sub.1-4 alkyl).sub.2, C.dbd.CHCl, C.dbd.CHCN, N--C.sub.1-4 alkyl, N-acetyl, SO.sub.2 and SO;X.sub.2 --is selected from N.dbd., CH.sub.2 --, CH.dbd., C(O)--, O--, and S--;R.sub.1 represents C.sub.1-4 alkyl;Y is selected from CH and N;n is 0, 1 or 2;q is 1 or 2;R.sub.2 is C.sub.1-6 alkyl optionally incorporating a heteroatom selected from N, O and S;D is cyclohexane or benzene; andE is a saturated or unsaturated 5- or 6-membered heterocycle incorporating 1, 2 or 3 heteroatoms selected from O, N, and S, wherein E is optionally substituted with 1 or 2 substituents selected from halogen, C.sub.1-4 alkyl and halogen-substituted C.sub.1-4 alkyl;and acid addition salts, solvates and hydrates thereof.
Abstract: The present invention relates to a compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are .alpha.-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are .alpha.-1 antagonist compositions and a method for antagonizing .alpha.-1 receptors and treating BPH.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
August 11, 1998
Assignee:
Abbott Laboratories
Inventors:
Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, James F. Kerwin, Jr., Suzanne A. Lebold, Edmund L. Lee, John K. Pratt, Kevin B. Sippy, Karin R. Tietje, Diane M. Yamamoto
Abstract: Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives represented by the formula ##STR1## wherein A, B, D, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined in the description, compositions thereof and methods for preparing the compounds are described. The compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, pulmonary system, the gastrointestinal system and the endocrinologic system.
Type:
Grant
Filed:
January 17, 1997
Date of Patent:
August 11, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Bernard Pirotte, Philippe Lebrun, Pascal De Tullio, Fabian Somers, Jacques Delarge, Holger Claus Hansen, Flemming Elmelund Nielsen, John Bondo Hansen
Abstract: An acridine derivative metal complex of formula 1 or formula 2 having a large absorption in the near-infrared range and a reduced absorption in the visible range, which acridine derivative metal complex is used in a transparent recording medium: ##STR1## where M is a metal atom, and X is a negative ion.